Physician profile
Geoffrey Teehan
NPI 1558366237
$72,108.23
in general payments reported to CMS, 2019-2025
24 companies · $2,182 in 2025
The $2,182 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,092 · 2021: $7,758 · 2022: $35K · 2023: $7,733 · 2024: $380 · 2025: $2,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,660 · Food and Beverage: $2,441 · Consulting Fee: $585 · Travel and Lodging: $571 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,660.00 |
| Food and Beverage | $2,440.55 |
| Consulting Fee | $585.00 |
| Travel and Lodging | $571.00 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47,023.43 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $12,974.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $4,817.31 | 2020-2024 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $2,776.07 | 2019-2025 | Voyxact |
| Ani Pharmaceuticals, INC. | $1,175.00 | 2021 | |
| Vifor Pharma, INC. | $1,011.36 | 2019-2025 | Veltassa, Korsuva |
| Analog Devices INC. | $585.00 | 2025 | |
| Amgen INC. | $319.95 | 2019-2025 | Uplizna, Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.82 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $192.36 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $177.54 | 2019-2025 | |
| Scpharmaceuticals INC. | $177.15 | 2025 | |
| Travere Therapeutics, INC. | $127.22 | 2025 | Filspari |
| Novo Nordisk INC | $108.06 | 2024-2025 | Ozempic, Rybelsus |
| Cormedix INC. | $88.73 | 2024-2025 | Defencath, Defencath |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $83.65 | 2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $60.00 | 2024-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $39.14 | 2023 | Jesduvroq |
| Lilly USA, LLC | $30.53 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $30.11 | 2025 | Lupkynis |
| Akebia Therapeutics INC | $25.53 | 2019 | |
| Apellis Pharmaceuticals, INC. | $25.46 | 2025 | Empaveli |
| Biomerieux INC | $23.33 | 2019 | |
| Fresenius USA Marketing, INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Teehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.